/image%2F3334645%2F20201111%2Fob_fd07bb_sans-titre-1.jpg)
/image%2F3334645%2F20260815%2Fob_bc620d_776497617-2038408443455296-23321386311.jpg "What Makes Witch Hazel Effective? Science, Mechanisms, and Clinical Evidence")
/image%2F3334645%2F20260815%2Fob_0b61ff_1648b369-8789-4bda-ba8e-e0f14509b143.jpg "Witch Hazel and Its Health Benefits: What the Research Shows")
/image%2F3334645%2F20260813%2Fob_b43f9c_769309559-2140073886540951-57767507467.net%26_nc_cat%3D103%26_nc_ohc%3D4QRjV1Bt6mMQ7kNvwEXX8Hm%26sdl%3D0%26ccb%3D14-4%26oh%3D00_AQEewd55H0n7-7rqoPxlPHipVunD0UlbK_kX7bWw4GptTQ%26oe%3D6A840C87%26_nc_sid%3Da21977 "Theoretical Foundations of Cold Laser Water Imprinting")
/image%2F3334645%2F20260813%2Fob_c7a592_bdff188c-2305-4a08-bbd1-19ddd0b42cfe.jpg "Cold Laser-Based Water Imprinting: A Review of Exposure Duration and Proposed Mechanisms")
/image%2F3334645%2F20260812%2Fob_1114bb_aug-12-2026-03-02-57-pm.png "From Resonant Frequencies to Biological Effects: Experimental Extensions of the Resonant Recognition Model")
/image%2F3334645%2F20260810%2Fob_8634c6_oig1.yWdw_LTFGSh7hPhQqazw%3Fw%3D1024%26h%3D1024%26qlt%3D70%26p%3D0%26r%3D0%26o%3D4%26pid%3DImgGn "The Resonant Recognition Model: Searching for Hidden Frequencies in DNA and Proteins")
/image%2F3334645%2F20260806%2Fob_33a5c3_imefefzage-1-c.jpg "Soquelitinib: A Potential New Treatment for Inflammatory Diseases")
/image%2F3334645%2F20260805%2Fob_afeba9_766221654-1377354427854223-55085509030.net%26_nc_cat%3D107%26_nc_ohc%3Df91CASdi6pcQ7kNvwGY-dZI%26sdl%3D0%26ccb%3D14-4%26oh%3D00_AQGGIMtSjoq8bH-AjqOyCYJO-jCK3Ds3w2WAlVSahh6y0Q%26oe%3D6A796F59%26_nc_sid%3Da21977 "Deeper Molecular Signatures: Fluorescence, NMR, Terahertz, and Circularly Polarized Emission")
/image%2F3334645%2F20260804%2Fob_9e339a_763992749-1764300548032994-46344489975.jpg "Spectroscopic Fingerprinting of Molecules: Theory, Measurement, and Real-World Applications")
/image%2F3334645%2F20260802%2Fob_b5c418_f3795fe1-14d0-4417-bd7c-d91c613666b2.jpg "Alpha-Tocopherol and Skin Health: The Science Behind Vitamin E")
Soquelitinib : An Eczema Pill for Everyone? What Experts Say So Far
/image%2F3334645%2F20260401%2Fob_66d9c7_gemini-generated-image-u2xp2hu2xp2hu2x.png)
An Eczema Pill for Everyone? What Experts Say So Far
Early trial results for soquelitinib are turning heads. Here's what the data shows.
If you have eczema, symptom control is the name of the game, but the primary way in which that’s currently done involves jabbing yourself with a needle—no fun. The goal: Develop a daily pill that’s equally effective and just as safe to control eczema symptoms.
That pill may one day soon be on the way: Drugmaker Corvus Pharmaceuticals just released early trial results for an experimental pill called soquelitinib. Many people in the study saw major skin clearing. The drug works by blocking specific immune signals that cause inflammation, a new approach to treating eczema.
The Study Findings
The trial followed four groups of people with moderate to severe eczema. The first three groups were tracked for four weeks; the fourth for eight weeks. In the first three groups, 50% of people taking soquelitnib saw symptom improvement; in the final group, participants were split evenly: half got soquelitinib, half got a placebo. Researchers measured results using a standard eczema scoring system called the Eczema Area and Severity Index (EASI)—a tool clinicians use to measure eczema severity. After eight weeks, 75% of those on the drug hit a key benchmark called EASI-75, meaning their eczema symptoms (itch, redness, etc.) improved dramatically. The increase in efficacy from 50% to 75% with just one extra month of treatment is reason to be optimistic, says the company behind the drug. "The data shows that soquelitinib appears to be a safe, oral medicine," says Richard A. Miller, M.D., the CEO of Corvus Pharmaceuticals, who notes that symptom improvement continued even after people stopped taking the drug. "I am impressed with the results," says Albert S. Chiou, M.D., a dermatology professor and clinical research director at University Medical Center in Redwood City, CA, who worked on the trial. "The safety data is promising, and the efficacy data is compelling." Dr. Chiou says he was especially struck by how long the results lasted after people stopped treatment. That staying power suggests the drug may be changing the disease itself, not just managing symptoms. Eczema affects people differently depending on their immune makeup, which is one reason why current treatments don't work for everyone. Dr. Chiou says soquelitinib's ability to block multiple immune signals at once could make it useful for a wider range of patients, from those trying systemic treatment for the first time to those who haven't responded to other drugs.
Soquelitinib Pill : How Does Soquelitinib Work for Eczema?
The drug targets an enzyme called ITK, which plays a key role in driving immune-related inflammation. By blocking ITK, soquelitinib dials down the overactive immune response behind eczema and may also boost regulatory immune cells that help keep inflammation in check. The result, according to Corvus, looks something like a reset: The immune system recalibrates in a way that can last well beyond the treatment period, similar to how a vaccine creates lasting protection.
Other Treatments: Soquelitinib vs. Other Treatments
Current top-tier treatments for eczema include Dupixent, a popular injectable, and JAK inhibitors, a class of oral drugs that work well but carry more safety concerns. Early data suggests soquelitinib may match JAK inhibitors in effectiveness but with a cleaner safety profile. That combination matters. "One of the first questions patients ask when we discuss next steps after topicals is if there is a safe pill option," says Dr. Chiou. If the results hold up, soquelitinib could fill a real gap: an oral drug that works well and doesn’t raise major red flags. It could also help people who've already tried everything else. Dr. Chiou notes that the trial included participants who had been through prior treatments with limited success, and the new drug appeared to improve their symptoms.
The Road Ahead : What's Next?
The current trial was phase 1, meaning it was primarily assessing the medication’s safety. A phase 2 trial is expected to launch in 2026, enrolling 200 patients with moderate to severe eczema across a range of doses and a longer treatment period. Results are anticipated in 2027. Soquelitinib isn't the only drug of its kind in the pipeline. Aclaris Therapeutics is also developing ITK inhibitors for eczema, with one in early-stage testing and another already in human trials. For people living with eczema, the proliferation of new treatment options is something worth cheering. With the therapeutics playing field growing increasingly diverse, the odds are good that at least one of these medications will work for you.
(Source : HealthCentral)
